Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Fineline Cube May 9, 2026
Company Deals

Hengrui Pharmaceuticals Expands Greater Bay Area Presence with Hong Kong Office Launch and Cancer Foundation Partnership

Fineline Cube May 9, 2026
Company Deals

Fosun Pharma Secures Exclusive China Rights to InxMed’s FAK Inhibitors for Solid Tumor Treatment

Fineline Cube May 9, 2026
Company Deals

Harbour BioMed Joins $165M Cross Financing Round for Windward Bio to Advance Ultra-Long-Acting TSLP Immunotherapies

Fineline Cube May 8, 2026
Company Deals

Roche Acquires PathAI for $750M to Accelerate Digital Pathology and AI-Driven Diagnostic Transformation

Fineline Cube May 8, 2026
Policy / Regulatory

China’s National Drug Alliance Procurement Office Suspends Harbin Liqiang’s Loxoprofen Gel Patch Production and Imposes 18-Month VBP Ban

Fineline Cube May 8, 2026
Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Fineline Cube May 9, 2026
Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Fineline Cube May 9, 2026
Company Drug

Accutar Biotechnology Initiates Phase I Trial for ERα Targeting Degradation Molecule AC0682

Fineline Cube Oct 14, 2022

New Jersey-based Accutar Biotechnology Inc., which is heavily backed by Chinese funds, has announced the...

Policy / Regulatory R&D

CDE Releases Draft Guidelines for Extrapolating Adult Drug Data to Pediatric Use

Fineline Cube Oct 14, 2022

The Center for Drug Evaluation (CDE) has released the “Guidelines on Quantitative Methodology for Extrapolating...

Company Drug

RemeGen’s Telitacicept Receives FDA Orphan Drug Designation for Myasthenia Gravis

Fineline Cube Oct 13, 2022

China-based pharma firm RemeGen (HKG: 9995, SHA: 688331) has announced receiving Orphan Drug Designation (ODD)...

Company Deals

Jacobio Partners with Merck KGaA for KRAS G12C Inhibitor Clinical Study

Fineline Cube Oct 13, 2022

China-based Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has announced a clinical study collaboration partnership...

Company Medical Device

Hotgen Biotech Gains Regulatory Approvals in Saudi Arabia and India

Fineline Cube Oct 13, 2022

China-based Hotgen Biotech Co., Ltd (SHA: 688068) has announced receiving one certificate from the Saudi...

Company Drug

BeiGene’s Brukinsa Outperforms Imbruvica in Phase III ALPINE Study

Fineline Cube Oct 13, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that its Bruton’s...

Company

Hengrui Medicine’s Deputy GM Tao Weikang Resigns, Joins Qilu Pharma

Fineline Cube Oct 13, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) has announced that its deputy general manager...

Company Deals

Proxinse Medtech Raises Series A Funding for Endoscope Camera System

Fineline Cube Oct 13, 2022

Shenzhen Proxinse Medical Technology Co., Ltd, a provider of minimally invasive surgery endoscope camera systems...

Company Deals

AlphaLife Sciences Raises Series A+ Funding for Clinical Research SaaS

Fineline Cube Oct 13, 2022

China-based clinical research SaaS service provider AlphaLife Sciences has reportedly raised “tens of millions” of...

Company Drug

Aosaikang’s Neratinib Maleate API Market Filing Accepted by NMPA

Fineline Cube Oct 13, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that the market filing for its...

Drug Policy / Regulatory

Azvudine Included in China’s COVID-19 Treatment Protocol

Fineline Cube Oct 12, 2022

The National Healthcare Commission and the National Administration of Traditional Chinese Medicine have released a...

Company Drug

NMPA Approves IND Filing for Henan Genuine Biotech’s Long-Acting HIV Drug CL-197

Fineline Cube Oct 12, 2022

China-based Henan Genuine Biotech Co., Ltd’s investigational new drug (IND) filing for its oral long-acting...

Company Deals

WuXi Biologics Partners with Toregem BioPharma on Anti-USAG-1 Monoclonal Antibody

Fineline Cube Oct 12, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has entered into...

Company Deals

BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development

Fineline Cube Oct 12, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership...

Company Medical Device

NMPA Approves Beijing Union Strong’s Intracranial Aneurysm Surgical Planning Software

Fineline Cube Oct 12, 2022

The National Medical Products Administration (NMPA) has approved the marketing of Beijing Union Strong Technology...

Company Deals

Aier Eye Hospital Group Plans IPO on ChiNext Board

Fineline Cube Oct 12, 2022

China-based ophthalmic medical services provider Aier Eye Hospital Group Co., Ltd (SHE: 300015) is set...

Company Deals

BeiGene Partners with Immune-Onc for Clinical Development of Myeloid Checkpoint Inhibitors

Fineline Cube Oct 12, 2022

China-based biotech BeiGene (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a clinical study...

Company Deals

Cyagen Biosciences Partners with Neurophth for Ophthalmology AAV Capsid Development

Fineline Cube Oct 12, 2022

Cyagen Biosciences, a provider of custom-engineered mouse and rat models with operations in the US...

Company Deals

IASO Biotherapeutics Licenses CD19 Binder to Cabaletta Bio for Autoimmune Diseases

Fineline Cube Oct 12, 2022

China-based IASO Biotherapeutics has announced a licensing agreement with US firm Cabaletta Bio Inc. (NASDAQ:...

Company Drug

Henlius Biotech’s HanBeiTai Biosimilar Accepted for Review by CDE

Fineline Cube Oct 12, 2022

Shanghai Henlius Biotech Inc. (HKG: 2696) has announced that a supplementary Biologic License Application (sBLA)...

Posts pagination

1 … 612 613 614 … 662

Recent updates

  • Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma
  • European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance
  • CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline
  • Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis
  • Innovent Biologics Secures Third Breakthrough Therapy Designation for IBI363 in MSS/pMMR Colorectal Cancer
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Wenda Pharmaceutical Secures NMPA Breakthrough Therapy Designation for NHWD-870 in Rare NUT Carcinoma

Company Drug

European Commission Approves Bristol Myers Squibb’s Sotyktu for Psoriatic Arthritis Following FDA Clearance

Company Deals

CureGene Pharmaceutical Secures RMB 300 Million Series C to Advance Global Clinical Pipeline

Company Drug

Keymed Biosciences Secures NMPA Breakthrough Therapy Designation for CM336 in AL Amyloidosis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.